Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia

Leukemia

Volumn 12, Issue 1, 1998, Pages 65-70

  Wilhelm, M ^a   Bueso Ramos, C ^b   O'Brien, S ^b   Pierce, S ^b   Keating, M ^b   Talpaz, M ^b   Kantarjian, H M ^b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow fibrosis; Chronic myeloid leukemia; Interferon alpha

Indexed keywords

ALPHA INTERFERON; RETICULIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYELOFIBROSIS; PRIORITY JOURNAL;

EID: 0031962954     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400885     Document Type: Article

References (40)

1. Kantarjian H, Deisseroth A, Kurzrock LR, Estrov Z, and Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
2. Lazzarino M, Morra E, Castello A, Inverardi D, Coci A, Pagnucco G, Magrini U, Zei G, Bernasconi C. Myelofibrosis in chronic granulocytic leukemia: clinicopathologic correlations and prognostic significance. Br J Haematol 1986; 64: 227-240.
3. Gralnick HR, Harbor J, Vovel C. Myelofibrosis in chronic granulocytic leukemia. Blood 1971; 37: 152-162.
4. Clough V, Geary CG, Hashimi K, Davson J, Knowlson T. Myelofibrosis in chronic granulocytic leukemia. Br J Haematol 1979; 42: 515-526.
5. Beelen DW, Graeven U, Elmaagacli AH et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-2990.
6. Kantarjian HM, Smith TL, O'Brien S et al Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995; 122: 254-261.
7. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
8. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
9. Allan N, Richards S, Shepard P et al UK Medical Research Council randomized, multicenter trial of interferon-alpha n1 for chronic myeloid leukemia - improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
10. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of inteferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
11. Thiele J, Kvasnicka HM, Niederle N et al The impact of Interferon vs busulfan therapy on the reticulin stain measured fibrosis in CML - a comparative morphometric study on sequential trephine biopsies. Ann Hematol 1995; 70: 121-128.
12. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer 1987; 59: 1739-1743.
13. Soil E, Massumoto C, Clift RA, Buckner CD, Appelbaum FR, Storb R, Sale G, Hackman R, Martin P. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667-4673.
14. Kantarjian HM, Smith TL, McCredie KB er al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.
15. Thiele J, Kvasnicka HM, Zankovich R, Fischer R, Diehl V. Parameters of predictive value in chronic myeloid leukemia - the prognostic impact of histopathological variables in a multivariate regression analysis. Leuk Lymphoma 1991; 4: 63-74.
16. Thiele J, Kvasnicka HM, Titius BR, Parpert U, Nebel R, Zankovich R, Dienemann D, Stein H, Diehl V, Fischer R. Histological features of prognostic significance in CML - immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann Hematol 1993; 66: 291-302.
17. O'Brien S, Kantarjian HM, Shtalrid M, Blick M, Beran M, Talpaz M. Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Hematol Pathol 1988; 2: 25-29.
18. Wang JC, Lang HD, Lichter S, Weinstein M, Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with rnyelofibrosis and myeloid metaplasia. Br J Haematol 1992; 80: 184-188.
19. 1-positive chronic myelogenous leukemia. Blood 1978; 51: 1039-1044.
20. Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood 1989; 74: 2330-2334.
21. Rosenfeld M, Keating A, Bowen-Pope DF, Singer JW, Ross R. Responsiveness of the in vitro hematopoietic microenvironment to platelet-derived growth factor. Leukemia Res 1985; 9: 427-434.
22. Groopman JE. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med 1980; 92: 857-858.
23. MacCarthy DM. Fibrosis of the bone marrow: content and causes. Br J Haematol 1985; 59: 1-7.
24. Buhr T, Choritz H, Georgii A. The impact of megakaryocyte proliferation for the evolution of myelofibrosis. Histological follow-up study in 186 patients with chronic myeloid leukemia. Virchows Arch 1992; 420: 473-478.
25. Thiele J, Wienhold S, Zankovich R, Fischer R. A histomorphometrical analysis of trephine biopsies of bone marrow from 65 patients with chronic myeloid leukemia - classification of patients into subgroups with different survival patterns. Anal Quant Cytol Histol 1990; 12: 103-116.
26. Yonekura S, Nagao T, Arimori S. Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia. Br J Haematol 1985; 61: 93-99.
27. Kamiyama R. Fibrous long spacing-like fibers in the bone marrow of myeloproliferate disorder. Virchows Arch 1982; 39: 285-291.
28. Bernabei P, Arcangeli A, Casini M, Grossi A, Padovani R, Rossi Ferrini P. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease. Br J Haematol 1986; 63: 353-357.
29. Katoh O, Kimuara A, Itoh T, Kuramoto A. Platelet-derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 1990; 35: 145-150.
30. Kimura A, Katoh O, Kuramoto A. Effects of platelet-derived growth factor, epidermal growth factor and transforming growth factor-β on the growth of human marrow fibroblasts. Br J Haematol 1988; 69; 9-12.
31. Katoh O, Kimura A, Kuramota A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol 1988; 27: 276-280.
32. Francis GE, Michaelevicz R, Wickremasinghe RG. Chronic myeloid leukaemia and the Philadelphia translocation: do the c-sis oncogene and platelet-derived growth factor provide the link? Leukemia Res 1983; 7: 817-820.
33. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpI-deficient mice. Science 1994; 265: 1445-1447.
34. de Sauvage FJ et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 1994; 369: 533-538.
35. Bartley TD et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpI. Cell 1994; 77: 1117-1124.
36. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M. Altered levels of interleukin-1β and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 1994; 84: 3142-3147.
37. Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood 1991; 78: 2400-2406.
38. McLaughlin P, Islam A, Barcos M, Meade P, Ozer H, Gavigan M, Henderson E, Han T. Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia. Blood 1988; 72: 936-939.
39. Bardawil RG, Grovers C, Ratain MJ, Golomb HM, Vardiman JW. Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2-interferon for hairy cell leukemia. Am J Clin Pathol 1986; 85: 194-201.
40. Naeim F, Jacobs AD. Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha 2-interferon. Hum Pathol 1985; 16: 1200-1205.